
    
      This study is a Phase 2 randomized, double-blinded, multi-center, parallel group,
      placebo-controlled evaluation of the safety and efficacy of SAF312 dose 1 and dose 2 eye
      drops versus placebo used twice-daily in both eyes for 12 weeks. Eligible subjects will have
      undergone refractive surgery (PRK or LASIK) in both eyes at least 4 months prior to
      Screening, and have been suffering from chronic ocular pain as a result of the their surgery.
      Eligible patients must also demonstrate chronicity of the pain at Baseline Visit as described
      in inclusion criteria. Overall approximately 150 subjects will be enrolled in the study and
      randomized to one of 3 study arms in 1:1:1 ratio
    
  